Lumenis Surgical Lasers Used in 100% of Hospitals on U.S. News & World Report Best Hospitals Honor Roll

Logo
July 20, 2021 13:02 UTC

Top hospitals from coast to coast rely on Lumenis holmium laser and CO2 surgical laser technologies to deliver outstanding patient care.

YOKNE'AM ILLIT, Israel--(BUSINESS WIRE)-- Lumenis Ltd, the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, is pleased to report that 100% of the hospitals named to U.S. News and World Report’s exclusive Best Hospitals Honor Roll have chosen Lumenis surgical lasers in their approach to delivering outstanding patient care. All of these prominent institutions use Lumenis technologies, with a majority employing the company’s flagship products: the groundbreaking, patent-protected Lumenis MOSES™ holmium laser technology and the pioneering Lumenis UltraPulse® DUO CO2 surgical laser system.

The Lumenis holmium laser with MOSES technology is proven to deliver many clinical and economic advantages for kidney stones1 and enlarged prostate2—two common procedures in many hospitals. Nearly universal adoption among these 20 top hospitals shows the strong trend toward standardization to MOSES technology. With MOSES, surgeons ablate stones with up to 85% higher efficiency3 and 20% shorter procedure times.1 For enlarged prostate surgery, MOSES has turned gold-standard HoLEP surgery from an overnight stay into a same-day, catheter-free discharge,4 creating a better patient experience while freeing hospital beds for acute care. Similarly, the tissue-sparing precision of the UltraPulse DUO CO2 laser has revolutionized challenging procedures, such as transoral microsurgery and minimally invasive treatment of uterine fibroids and endometriosis. Lumenis lasers offer multi-specialty flexibility in busy medical centers, with applications in urology, gynecology, otolaryngology, neurology and orthopedics.

“We are pleased to see every one of the outstanding hospitals on the Best Hospitals Honor Roll uses Lumenis surgical lasers,” said Tzipi Ozer-Armon, CEO, Lumenis. “At Lumenis, our mission is to deliver better technology for better patient care. We believe that one way to achieve this is through innovation and collaboration with leading surgeons and hospitals around the world. The end result is that Lumenis technologies are helping exceptional hospitals deliver exceptional patient care.”

Brad Oliver, Lumenis President of the Americas, pointed out that top hospitals lead by example, choosing technologies like Lumenis surgical lasers based on strong clinical evidence—and other hospitals take note. “The clinical advantages, as well as efficiencies in patient care, make Lumenis lasers stand out from the competition. That’s why leading hospitals on the Best Hospitals Honor Roll choose Lumenis. And any hospital in the world can offer those same advantages to their patients with Lumenis lasers.”

1. Ibrahim A et al. Double-Blinded Prospective Randomized Clinical Trial Comparing Regular and MOSES Modes of Holmium Laser Lithotripsy. J Endourology. 2020;34(5):624-628.

2. Kavoussi NL et al. MOSES Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Control Trial. J Urol. 2021 Feb 22.

3. Bench test results may not necessarily be indicative of clinical performance.

4. Agarwal DK et al. Same Day Discharge is a Successful Approach for the Majority of Patients Undergoing Holmium Laser Enucleation of the Prostate. Eur Urol Focus. 2021 Jan 4;S2405-4569(20)30320-5.

About Lumenis

Lumenis is a global leader in the field of minimally invasive clinical solutions for the surgical, ophthalmology and aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including laser, intense pulsed light (IPL) and radio frequency (RF). For 50+ years, Lumenis' groundbreaking products have redefined medical treatments and set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information, visit www.lumenis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005325/en/

Contacts

Genevieve Britton
+1.512.774.0735 (c)
genevieve@pascalecommunications.com

Source: Lumenis

Back to news